Lu-177-DGUL

N/A

Report date: 2025/11/20 13:28:18

NME

Base Information

Drug NameLu-177-DGUL

Drug Alias NamePSMA targeting radiotracerLu-177-DGUL177Lu-DOTA-GULPSMA-D GUL

ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionProstate-Specific Membrane Antigen modulators

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsProstatic Neoplasms, Castration-ResistantProstatic NeoplasmsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesCellbion Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesCellbion Co Ltd

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A